Abstract
Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11, is a non-receptor protein tyrosine phosphatase that expressed in cytoplasmic. Served as an important hub, SHP2 provide crosstalk for several intracellular pathways such as Ras-Raf-MEK-ERK, PI3K-AKT-mTOR, JAK-STAT, and PD-1/PD L-1 pathways in either growth factor-dependent or immune-dependent manner. Both the classical phosphatase-dependent and -independent roles of SHP2 are involved in the pathologic process of several diseases, making SHP2 a promising drug target. PTPN11 mutations, including gain-of-function (GOF) mutation and loss-of-function (LOF) mutation, are frequently observed in numerous diseases. These mutations are characterized by structural rearrangement and electric potential change, leading to the alteration of enzyme activity and binding affinity toward phosphotyrosine peptide. The dynamic conformational transition of SHP2 under either physiological or pathological conditions provides directions for the drug discovery targeting SHP2. SHP2-targeted inhibitors, proteolysis-targeting chimera (PROTAC)-based degraders, and activators have shown therapeutic promise against numerous diseases. To date, nine allosteric inhibitors are undergoing clinical assessment as mono- or combined therapy for treating solid tumors or adaptive resistant cancers. In this chapter, we comprehensively summarize the multifaceted functions of SHP2 and the structural basis of SHP2 under different conditions. Additionally, the challenges and prospects of SHP2-targeted drug discovery are also discussed. This chapter will not only facilitate the underlying pathological mechanisms of SHP2-associated diseases but also provide a landscape for the advances of SHP2-targeted drug discovery.
Similar content being viewed by others
References
An H, Zhao W, Hou J et al (2006) SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 25(6):919–928
Bentires-Alj M, Paez JG, David FS et al (2004) Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64(24):8816–8820
Breitkopf SB, Yang X, Begley MJ et al (2016) A cross-species study of PI3K protein-protein interactions reveals the direct interaction of P85 and SHP2. Sci Rep 6:20471
Chan G, Kalaitzidis D, Usenko T et al (2009) Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood 113(18):4414–4424
Dance M, Montagner A, Salles JP et al (2008) The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 20(3):453–459
Denu JM, Lohse DL, Vijayalakshmi J et al (1996a) Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. Proc Natl Acad Sci U S A 93(6):2493–2498
Denu JM, Stuckey JA, Saper MA et al (1996b) Form and function in protein dephosphorylation. Cell 87(3):361–364
Fragale A, Tartaglia M, Wu J et al (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23(3):267–277
Grossmann KS, Rosário M, Birchmeier C (2010) The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 106:53–89
Guo W, Xu Q (2020) Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds. J Pharmacol Sci 144(3):139–146
Halliday PR, Blakely CM, Bivona TG (2019) Emerging targeted therapies for the treatment of non-small cell lung cancer. Curr Oncol Rep 21(3):21
Hof P, Pluskey S, Dhe-Paganon S et al (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92(4):441–450
Hui E, Cheung J, Zhu J et al (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355(6332):1428–1433
Hyun S, Shin D (2021) Small-molecule inhibitors and degraders targeting KRAS-driven cancers. Int J Mol Sci 22(22):12142
Imaide S, Riching KM, Makukhin N et al (2021) Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nat Chem Biol 17(11):1157–1167
LaRochelle JR, Fodor M, Xu X et al (2016) Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2. Biochemistry 55(15):2269–2277
LaRochelle JR, Fodor M, Ellegast JM et al (2017) Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. Bioorg Med Chem 25(24):6479–6485
Li L, Modi H, McDonald T et al (2011) A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells. Blood 118(6):1504–1515
Liu Q, Qu J, Zhao M et al (2020) Targeting SHP2 as a promising strategy for cancer immunotherapy. Pharmacol Res 152:104595
Liu Y, Yang X, Wang Y et al (2021) Targeting SHP2 as a therapeutic strategy for inflammatory diseases. Eur J Med Chem 214:113264
Martinelli S, Torreri P, Tinti M et al (2008) Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet 17(13):2018–2029
Mohi MG, Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17(1):23–30
Ohtani T, Ishihara K, Atsumi T et al (2000) Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12(1):95–105
Ostman A, Hellberg C, Böhmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6(4):307–320
Pádua RAP, Sun Y, Marko I et al (2018) Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nat Commun 9(1):4507
Qiu W, Wang X, Romanov V et al (2014) Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol 14:10
Rehman AU, Rahman MU, Khan MT et al (2018) The landscape of protein tyrosine phosphatase (Shp2) and cancer. Curr Pharm Des 24(32):3767–3777
Rodriguez-Viciana P, Warne PH, Dhand R et al (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370(6490):527–532
Schneeberger VE, Luetteke N, Ren Y et al (2014) SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis 35(8):1717–1725
Sheppard KA, Fitz LJ, Lee JM et al (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 574(1–3):37–41
Song Z, Wang M, Ge Y et al (2021a) Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharm Sin B 11(1):13–29
Song Y, Zhao M, Wu Y et al (2021b) A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. Acta Pharm Sin B 11(3):750–762
Song Y, Zhao M, Zhang H et al (2022a) Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol Ther 230:107966
Song Y, Wang S, Zhao M et al (2022b) Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy. J Med Chem 65(4):3066–3079
Song Y, Yang XY, Wang S, Zhao M, Yu B (2022c) Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery. Med Res Rev 42(5):1781–1821
Song Y, Yang X, Yu B (2022d) KRAS Q61H mutation confers cancer cells with acquired resistance to SHP2 inhibition. Pharmaceutic Fronts 04(01):e40–e42
Tang K, Jia YN, Yu B et al (2020) Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. Eur J Med Chem 204:112657
Tartaglia M, Mehler EL, Goldberg R et al (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29(4):465–468
Tartaglia M, Niemeyer CM, Fragale A et al (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and_ acute myeloid leukemia. Nat Genet 34(2):148–150
Tartaglia M, Martinelli S, Cazzaniga G et al (2004) Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104(2):307–313
Tautz L, Critton DA, Grotegut S (2013) Protein tyrosine phosphatases: structure, function, and implication in human disease. Methods Mol Biol 1053:179–221
Tsutsumi R, Ran H, Neel BG (2018) Off-target inhibition by active site-targeting SHP2 inhibitors. FEBS Open Bio 8(9):1405–1411
Wang RR, Liu WS, Zhou L et al (2020) Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics. J Biomol Struct Dyn 38(5):1525–1538
Wu X, Guo W, Wu L et al (2012) Selective sequestration of STAT1 in the cytoplasm via phosphorylated SHP-2 ameliorates murine experimental colitis. J Immunol 189(7):3497–3507
Xie J, Si X, Gu S et al (2017) Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment. J Med Chem 60(24):10205–10219
Yang X, Wang Z, Pei Y et al (2021) Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. Eur J Med Chem 218:113341
Yangchun M, WenYu Y, Liang Z et al (2022) Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition. Mol Divers 26(3):1567–1580
Yu WM, Hawley TS, Hawley RG et al (2003) Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 22(38):5995–6004
Yu J, Deng R, Zhu HH et al (2013a) Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1, and SH2-tyrosine phosphatase Shp2. J Biol Chem 288(6):3823–3830
Yu ZH, Xu J, Walls CD et al (2013b) Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J Biol Chem 288(15):10472–10482
Yu ZH, Zhang RY, Walls CD et al (2014) Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. Biochemistry 53(25):4136–4151
Yu K, Yin Y, Ma D et al (2020) Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4. Int Immunopharmacol 80:106008
Zhang SQ, Tsiaras WG, Araki T et al (2002) Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 22(12):4062–4072
Zhang RY, Yu ZH, Chen L et al (2020) Mechanistic insights explain the transforming potential of the T507K substitution in the protein tyrosine phosphatase SHP2. J Biol Chem 295(18):6187–6201
Zhang H, Yang X, Song Y, Yu B (2022) Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcome multidrug resistance in cancer. Future Med Chem 14(8):527–529
Zheng M, Liu Y, Wu C et al (2021a) Novel PROTACs for degradation of SHP2 protein. Bioorg Chem 110:104788
Zheng M, Huo J, Gu X et al (2021b) Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP. J Med Chem 64(11):7839–7852
Zhu G, Xie J, Kong W et al (2020) Phase separation of disease-associated SHP2 mutants underlies MAPK hyperactivation. Cell 183(2):490–502
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Song, Y., Yu, B. (2023). Targeting SHP2 for Cancer Treatment: Advances and Prospects. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_256-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_256-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences